#USA #Miami Lakes #Cordis #SELUTION SLR #Drug-Eluting Balloons

Cordis Launches the SELUTION Global Coronary Registry

Cordis, a prominent name in interventional cardiovascular technologies, has recently kicked off a significant new initiative: the SELUTION Global Coronary Registry. This ambitious project aims to recruit up to 10,000 patients globally and will become one of the largest databases dedicated to coronary drug-eluting balloons (DEBs) to date. The purpose of this registry is not just to gather numbers but to track real-world patient outcomes related to the SELUTION SLR™ Drug-Eluting Balloon over a period of up to five years. This wealth of data is intended to complement existing results from ongoing randomized clinical trials, thereby enhancing the overall understanding and application of DEB technology in clinical settings.

Expanding Evidence for Clinical Impact

The SELUTION SLR™ DEB has already shown promising effectiveness in preliminary studies, demonstrating sustained Sirolimus release in tissues for 90 days. Further proof-of-concept evaluations have revealed favorable late lumen loss statistics, indicating excellent performance metrics. The registry will build upon the findings of five ongoing Level-1 randomized trials and insights from recently published peripheral experiences, which have also shown competitive results. Such robust data collection emphasizes Cordis's commitment to producing valuable clinical evidence that can potentially alter the treatment landscape.

Renowned interventional cardiologist Dr. Ajay J. Kirtane from Columbia University recently remarked on the significance of this registry, stating, "Drug-eluting balloons represent one of the most exciting advancements in coronary intervention." He highlighted that this extensive real-world study will help practitioners comprehend how and where technology like the SELUTION SLR™ DEB can offer the best outcomes, ultimately benefiting patient care.

An Esteemed Steering Committee

To ensure the credibility and impact of the SELUTION Global Coronary Registry, Cordis has gathered an impressive steering committee composed of distinguished clinical experts from various parts of the world:

• - Dr. Ajay Kirtane (Chairman of the Steering Committee, Columbia University Irving Medical Center, USA)
• - Professor Alexandre Abizaid (Director of Interventional Cardiology, Incor – Universidade de Sao Paulo, Brazil)
• - Professor Robert Byrne (Director of Cardiology, CVRI Dublin, Mater Private Network, Ireland)
• - Dr. Nieves Gonzalo (Interventional Cardiologist, Hospital Clinico San Carlos, Spain)
• - Dr. Robert Yeh (Director of Smith Center for Outcomes Research, USA)

These professionals bring extensive expertise and a collaborative commitment to advancing patient-focused cardiovascular care.

Dr. George Adams, the Chief Medical Officer at Cordis, stated, "Our foundation is built on a dedication to clinical evidence. By placing patients at the forefront of our technological advancements, we aim to back our innovations with the best possible evidence. The launch of this registry reinforces our pledge to improve cardiovascular care fundamentally. We eagerly anticipate sharing groundbreaking results from this initiative later this year.”

About SELUTION SLR™ DEB

Currently available in over 40 countries, the SELUTION SLR™ DEB is a cutting-edge advancement in drug-eluting balloon technology. Its design facilitates a sustained release of Sirolimus without the need for a permanent implant, which allows healthcare providers the flexibility to